Literature DB >> 15743544

Migraine headache: options for acute treatment.

Frederick R Taylor1.   

Abstract

The optimal acute treatment of migraine requires recognition of the multitude of migraine presentations, the frequency of total attacks, and number of days of headache disability. These initial diagnostic steps are initiated in the waiting room, but phase-specific and stratified treatment selection requires having mutual understanding, trust, and belief through extensive discussion. The imperative acute treatment goal must be to treat early, but not too often, a fact represented by a 75% or better occurrence of pain freedom at 2 hours with two or fewer drug doses averaging 2 or fewer days a week. Migraine-specific therapy best wins the race against time and allodynia. Employing this formulary, multiple triptan formulations and phase and stratified patient-centered therapy creates success.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15743544     DOI: 10.1007/s11910-005-0004-5

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  40 in total

1.  The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine.

Authors:  R Burstein; M F Cutrer; D Yarnitsky
Journal:  Brain       Date:  2000-08       Impact factor: 13.501

Review 2.  Pharmacologic management of acute attacks of migraine and prevention of migraine headache.

Authors:  Vincenza Snow; Kevin Weiss; Eric M Wall; Christel Mottur-Pilson
Journal:  Ann Intern Med       Date:  2002-11-19       Impact factor: 25.391

3.  2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study.

Authors:  R B Lipton; W F Stewart; R Cady; C Hall; S O'Quinn; T Kuhn; D Gutterman
Journal:  Headache       Date:  2000 Nov-Dec       Impact factor: 5.887

4.  Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials.

Authors:  R K Cady; F Sheftell; R B Lipton; S O'Quinn; M Jones; D G Putnam; A Crisp; A Metz; S McNeal
Journal:  Clin Ther       Date:  2000-09       Impact factor: 3.393

5.  Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial.

Authors:  R B Lipton; W F Stewart; A M Stone; M J Láinez; J P Sawyer
Journal:  JAMA       Date:  2000 Nov 22-29       Impact factor: 56.272

6.  Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients.

Authors:  Stewart Tepper; Christopher Allen; David Sanders; Alison Greene; Stephen Boccuzzi
Journal:  Headache       Date:  2003-01       Impact factor: 5.887

Review 7.  Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.

Authors:  David Dodick; Richard B Lipton; Vincent Martin; Vasilios Papademetriou; Wayne Rosamond; Antoinette MaassenVanDenBrink; Hassan Loutfi; K Michael Welch; Peter J Goadsby; Steven Hahn; Susan Hutchinson; David Matchar; Stephen Silberstein; Timothy R Smith; R Allan Purdy; Jane Saiers
Journal:  Headache       Date:  2004-05       Impact factor: 5.887

8.  Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.

Authors:  Fred D Sheftell; Michele Feleppa; Stewart J Tepper; Michel Volcy; Alan M Rapoport; Marcelo E Bigal
Journal:  Headache       Date:  2004 Jul-Aug       Impact factor: 5.887

9.  Rapid and sensitive paradigm for screening patients with headache in primary care settings.

Authors:  Morris Maizels; Raoul Burchette
Journal:  Headache       Date:  2003-05       Impact factor: 5.887

Review 10.  Safety profile of the triptans.

Authors:  Stewart J Tepper; David Millson
Journal:  Expert Opin Drug Saf       Date:  2003-03       Impact factor: 4.250

View more
  2 in total

1.  Production of ultrafine sumatriptan succinate particles for pulmonary delivery.

Authors:  Zong-Yang Yang; Yuan Le; Ting-Ting Hu; Zhigang Shen; Jian-Feng Chen; Jimmy Yun
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.580

Review 2.  A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States.

Authors:  Linda Harris; Gilbert L'Italien; Thomas O'Connell; Zacharia Hasan; Susan Hutchinson; Sylvia Lucas
Journal:  Adv Ther       Date:  2021-05-31       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.